Ampliphi Biosciences (APHB) Stock Price, News & Analysis

Company Overview

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $2.11 to $2.30
• 50-Day Range: N/A
• 52-Week Range: $0.15 to $1.37
• Volume: 8,366 shs
• Average Volume: 842,200 shs
• Market Capitalization: $73.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APHB Stock Analysis - Frequently Asked Questions

How were Ampliphi Biosciences' earnings last quarter?

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) issued its quarterly earnings results on Monday, March, 25th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.07.

How do I buy shares of Ampliphi Biosciences?

Shares of APHB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Ampliphi Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ampliphi Biosciences investors own include Navios Maritime Partners (NMM), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Protalix BioTherapeutics (PLX), Athersys (ATHX) and Corbus Pharmaceuticals (CRBP).

Company Calendar

• Last Earnings: 3/25/2019
• Today: 12/11/2024

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:APHB
• Previous Symbol: AMEX:APHB
• CUSIP: N/A
• CIK: 921114
• Web: www.ampliphibio.com
• Phone: +1-804-8272524
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,469,000
• Free Float: N/A
• Market Cap: $73.63 million
• Optionable: Not Optionable
• Beta: N/A